贝伐珠单抗联合紫杉醇和卡铂对卵巢癌患者的治疗价值

Therapeutic value of bevacizumab combined with paclitaxel and carboplatin on ovarian cancer

目的研究贝伐珠单抗联合紫杉醇和卡铂对卵巢癌患者的治疗价值。方法队列研究。抽取2019年1月至2021年12月三门峡市中心医院收治的卵巢癌患者60例,按随机数字表法分为对照组和研究组,每组30例。对照组采用紫杉醇联合卡铂治疗,研究组在对照组基础上采用贝伐珠单抗治疗。对比两组疗效、治疗前后炎症因子[白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、干扰素-γ(IFN-γ)]水平、肿瘤标志物[糖类抗原153(CA153)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平及不良反应发生率。结果研究组总有效率(63.33%,19/30)高于对照组(36.67%,11/30),P<0.05。治疗后,研究组IL-6、IL-10水平低于对照组,IFN-γ水平高于对照组(P<0.05);治疗后,研究组CA153、CA125、CEA水平低于对照组(P<0.05)。研究组不良反应发生率(16.67%,5/30)与对照组(10.00%,3/30)比较差异未见统计学意义(P>0.05)。结论贝伐珠单抗联合紫杉醇和卡铂治疗卵巢癌可提升疗效,减轻机体炎症,降低肿瘤标志物水平,且治疗安全性良好。

ObjectiveTo study the value of bevacizumab combined with paclitaxel and carboplatin in the treatment of ovarian cancer patients.MethodsA total of 60 patients with ovarian cancer treated in Sanmenxia Central Hospital from January 2019 to December 2021 were selected for the cohort study.And they were divided into a control group and a study group according to the random number table method,with 30 cases in each group.The control group was treated with paclitaxel combined with carboplatin,and the study group was treated with bevacizumab based on the treatment of the control group.The curative effect,preoperative and postoperative levels of inflammatory factors including interleukin-6(IL-6),interleukin-10(IL-10)and interferon-γ(IFN-γ),tumor markers including carbohydrate antigen 153(CA153),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA),and incidence of adverse reactions were compared between the two groups.ResultsThe total effective rate of the study group(63.33%,19/30)was higher than that of the control group(36.67%,11/30),P<0.05.After treatment,the levels of IL-6 and IL-10 in the study group were lower than those in the control group,while the level of IFN-γin the study group was higher(P<0.05).After treatment,the levels of CA153,CA125 and CEA in the study group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(16.67%,5/30)and the control group(10.00%,3/30),P>0.05.ConclusionsBevacizumab combined with paclitaxel and carboplatin in the treatment of ovarian cancer can improve the treatment efficacy,reduce the body inflammation,and reduce the level of tumor markers,with good safety.